Mosanna Therapeutics, a Basel-based biotechnology company, has closed a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of the molecule MOS118 and for regulatory activities in preparation of the first Phase 1b clinical trial. Mosanna is developing the advanced small molecule MOS118, formerly know as AVE0118, for the treatment of metabolic obstructive sleep apnea.
VISCHER has advised Mosanna Therapeutics since its incorporation on all Swiss legal matters. The corporate/m&a team includes partner Matthias Staehelin (pictured left) and Timothy Woodtli (associate, pictured right).